Clinical decision support tool for adenomyosis impact on fertility outcomes

Clinical decision support tool for adenomyosis impact on fertility outcomes targets a $2.4B = 800K IVF cycles/year globally (ICMART 2021) x 20% adenomyosis prevalence (literature estimate) x $15K avg cycle cost where diagnostic/prognostic tools capture 1% of cycle spend. Buyer is fertility clinic or hospital reproductive medicine department purchasing annual software licenses. total addressable market with low saturation and a year-over-year growth rate of 8-12% (IVF cycle volume growing 6-8% annually per CDC ART reports; adenomyosis diagnosis increasing with better imaging and awareness).

Key trends driving demand: AI-enhanced ultrasound and MRI interpretation -- enables automated measurement of junctional zone and myometrial features, making standardized adenomyosis scoring scalable across operators and clinics; Value-based care in fertility -- payers and employers offering IVF benefits demand outcome transparency, driving clinics to adopt tools that improve patient selection and success rate reporting; Regulatory clarity for clinical decision support -- FDA 510(k) exemptions and EU MDR pathways for non-diagnostic CDS software lower compliance burden, enabling faster market entry for validated calculators.